Oppenheimer restated their outperform rating on shares of Zura Bio (NASDAQ:ZURA - Free Report) in a research report released on Monday, Benzinga reports. Oppenheimer currently has a $16.00 price objective on the stock, down from their previous price objective of $17.00.
Zura Bio Stock Performance
ZURA traded up $0.28 during trading on Monday, reaching $2.85. The company had a trading volume of 342,494 shares, compared to its average volume of 282,638. Zura Bio has a 12 month low of $2.00 and a 12 month high of $15.86. The business's fifty day moving average price is $3.37 and its 200 day moving average price is $4.42.
Institutional Inflows and Outflows
Institutional investors have recently bought and sold shares of the stock. Armistice Capital LLC lifted its stake in Zura Bio by 66.3% in the third quarter. Armistice Capital LLC now owns 1,580,000 shares of the company's stock valued at $10,428,000 after buying an additional 630,000 shares in the last quarter. Suvretta Capital Management LLC acquired a new stake in shares of Zura Bio in the second quarter valued at approximately $23,370,000. Silverarc Capital Management LLC raised its holdings in shares of Zura Bio by 152.5% in the third quarter. Silverarc Capital Management LLC now owns 404,040 shares of the company's stock valued at $2,667,000 after purchasing an additional 244,040 shares during the last quarter. Lynx1 Capital Management LP acquired a new stake in shares of Zura Bio in the third quarter valued at approximately $65,000. Finally, Raymond James & Associates raised its holdings in shares of Zura Bio by 14.0% in the third quarter. Raymond James & Associates now owns 77,356 shares of the company's stock valued at $511,000 after purchasing an additional 9,481 shares during the last quarter. Institutional investors own 61.14% of the company's stock.
Zura Bio Company Profile
(
Get Free Report)
Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops ZB-168, an anti IL7R a inhibitor that impact on diseases driven by IL7 and TSLP biological pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development.
Featured Stories
Before you consider Zura Bio, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Zura Bio wasn't on the list.
While Zura Bio currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat's analysts have just released their top five short plays for May 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.
Get This Free Report
